HER2-Negative Metastatic Breast Cancer
CASE 2: HER2-Negative Chemotherapy-Resistant mBC
Kim W, 53-year-old postmenopausal woman of Asian decent from Morristown, New Jersey, who worked as an accountant.
2013: Presented to PCP after finding a lump in right breast. Referred to oncologist for standard diagnostic workup.
Diagnosed with infiltrating ductal adenocarcinoma; 5.5-cm lesion in lower outer quadrant of right breast and palpable ipsilateral axillary nodes, which were FNA+ for adenocarcinoma
Fluorescence in situ hybridization determined HER2-negative/ER+/PR+ tumor
Patient was able to work and carry out daily activities (KPS score 94)
Bone scan and chest diagnostic CT revealed no metastases
Neoadjuvant therapy begun with dose-dense AC: doxorubicin 60 mg/m2 IV q2 weeks followed by weekly paclitaxel 80 mg/m2 x 12
Patient underwent breast-conserving therapy (malignant cells in 7 axillary lymph nodes)
Surgery followed by chest wall and regional lymph node radiation therapy (5x/week for 6 weeks). Started nonsteroidal aromatase inhibitor.
5 months after adjuvant chemotherapy treatment, patient complained of bone pain.
Patient was unable to work, but could carry out self care and some home upkeep
Bone scan and CT scan revealed several metastases: 2 lesions on right leg bone measuring 2-3 cm, 2 lesions on liver measuring 2-3 cm; 1 lesion on lung measuring 2-3 cm
Patient identified as potentially resistant to taxane (having progressed within 12 months of last adjuvant therapy)
Liver biopsy and pathology showed metastases consistent with original breast cancer. Patient diagnosed with stage IV cancer
Histology confirmed HER2-negative/ER+/PR+ disease. Began therapy with denosumab for bone metastases
Also received Xeloda 1000 mg/m2 PO BID day 1-14
Also received Xeloda 1000 mg/m2 PO BID day 1-14
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More